Literature DB >> 17467828

Predictive value of high sensitivity CRP in patients with diastolic heart failure.

Yoav Michowitz1, Yaron Arbel, Dov Wexler, David Sheps, Ori Rogowski, Itzhak Shapira, Shlomo Berliner, Gad Keren, Jacob George, Arie Roth.   

Abstract

BACKGROUND: C-reactive protein (CRP) has been tested in patients with systolic heart failure (HF) and mixed results have been obtained with regards to its potential predictive value. However, the role of C-reactive protein (CRP) in patients with diastolic HF is not established. We studied the predictive role of high sensitivity CRP (hsCRP) in patients with diastolic HF.
METHODS: HsCRP levels were measured in a cohort of CHF outpatients, 77 patients with diastolic HF and 217 patients with systolic HF. Concentrations were compared to a large cohort of healthy population (n=7701) and associated with the HF admissions and mortality of the patients.
RESULTS: Levels of hsCRP did not differ between patients with systolic and diastolic HF and were significantly elevated compared to the cohort of healthy subjects even after adjustment to various clinical parameters (p<0.0001). In patients with diastolic HF, hsCRP levels associated with New York Heart Association functional class (NYHA-FC) (r=0.31 p=0.01). On univariate Cox regression model hsCRP levels independently predicted hospitalizations in patients with systolic but not diastolic HF (p=0.047).
CONCLUSION: HsCRP concentrations are elevated in patients with diastolic HF and correlate with disease severity; their prognostic value in this patient population should be further investigated.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17467828     DOI: 10.1016/j.ijcard.2007.02.037

Source DB:  PubMed          Journal:  Int J Cardiol        ISSN: 0167-5273            Impact factor:   4.164


  17 in total

Review 1.  Obstructive sleep apnea syndrome and cardiovascular disease: The influence of C-reactive protein.

Authors:  Izolde Bouloukaki; Charalampos Mermigkis; Eleftherios M Kallergis; Violeta Moniaki; Eleni Mauroudi; Sophia E Schiza
Journal:  World J Exp Med       Date:  2015-05-20

2.  Personality and inflammation: the protective effect of openness to experience.

Authors:  Charles R Jonassaint; Stephen H Boyle; Cynthia M Kuhn; Ilene C Siegler; William E Copeland; Redford Williams
Journal:  Ethn Dis       Date:  2010       Impact factor: 1.847

3.  Locomotor Muscle Microvascular Dysfunction in Heart Failure With Preserved Ejection Fraction.

Authors:  Michael A Francisco; Joshua F Lee; Zachary Barrett-O'Keefe; H Jonathan Groot; Stephen M Ratchford; Kanokwan Bunsawat; Jeremy K Alpenglow; John J Ryan; Jose N Nativi; Russell S Richardson; D Walter Wray
Journal:  Hypertension       Date:  2021-11-01       Impact factor: 10.190

Review 4.  Role of m6A Methylation in the Occurrence and Development of Heart Failure.

Authors:  Shaowei Fan; Yuanhui Hu
Journal:  Front Cardiovasc Med       Date:  2022-06-24

5.  Lycopene dietary intervention: a pilot study in patients with heart failure.

Authors:  Martha J Biddle; Terry A Lennie; Gregory V Bricker; Rachel E Kopec; Steven J Schwartz; Debra K Moser
Journal:  J Cardiovasc Nurs       Date:  2015 May-Jun       Impact factor: 2.083

6.  Impact of HIV infection on diastolic function and left ventricular mass.

Authors:  Priscilla Y Hsue; Peter W Hunt; Jennifer E Ho; Husam H Farah; Amanda Schnell; Rebecca Hoh; Jeffrey N Martin; Steven G Deeks; Ann F Bolger
Journal:  Circ Heart Fail       Date:  2009-11-20       Impact factor: 8.790

Review 7.  Targeting interleukin-1 in heart failure and inflammatory heart disease.

Authors:  Benjamin W Van Tassell; Juan M Valle Raleigh; Antonio Abbate
Journal:  Curr Heart Fail Rep       Date:  2015-02

8.  Effects of interleukin-1 blockade with anakinra on aerobic exercise capacity in patients with heart failure and preserved ejection fraction (from the D-HART pilot study).

Authors:  Benjamin Wallace Van Tassell; Ross Arena; Giuseppe Biondi-Zoccai; Justin McNair Canada; Claudia Oddi; Nayef Antar Abouzaki; Arehzo Jahangiri; Raquel Appa Falcao; Michael Christopher Kontos; Keyur Bharat Shah; Norbert Felix Voelkel; Charles Anthony Dinarello; Antonio Abbate
Journal:  Am J Cardiol       Date:  2013-10-04       Impact factor: 2.778

9.  Prognostic value of biomarkers in heart failure: application of novel methods in the community.

Authors:  Shannon M Dunlay; Yariv Gerber; Susan A Weston; Jill M Killian; Margaret M Redfield; Véronique L Roger
Journal:  Circ Heart Fail       Date:  2009-07-29       Impact factor: 8.790

10.  Are there differences in acute phase inflammation markers regarding the type of heart failure?

Authors:  Ignacio J Sánchez-Lázaro; Luis Almenar-Bonet; Edelmiro Reganon-Salvador; Virtudes Vila-Liante; Vicenta Martínez-Sales; Luis Martínez-Dolz; Jaime Agüero-Ramón-Llin; Antonio Salvador-Sanz
Journal:  Heart Int       Date:  2011-10-21
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.